BioNTech SE

Earnings Call Insights Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition Mar. 10, 2026...

Jefferies lowered the firm’s price target on BioNTech (BNTX) to $138 from $151 and keeps a Buy rating on the shares. The company reported Q4 results and announc...

Last quarter's reported loss isn't the problem. Although it was slightly bigger than expected, the analyst community knew the company would likely remain in the...

(RTTNews) - Shares of BioNTech SE (BNTX) are moving down about 22 percent during Tuesday morning trading following the announcement of net loss in the fourth qu...

Ugur Sahin and Özlem Türeci, the co-founders of BioNTech, were given the Axel Springer Award in March 2021 in Berlin. (Photo by Bernd von Jutrczenka - Pool/Gett...

BioNTech SE ( (BNTX) ) just unveiled an announcement. BioNTech reported on March 10, 2026, that its 2025 revenues rose slightly to €2.87 billion, but it swung...

Biontech co-founders Ugur Sahin (L) and Ozlem Tureci rose to prominence during the Covid-19 pandemic, when their work on mRNA technology helped develop—together...

BioNTech (BNTX) announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Ozlem Tureci, M.D...

BioNTech (NasdaqGS:BNTX) is expanding its oncology pipeline through acquisitions, including Biotheseus. The company recently entered a collaboration with Brist...

Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study. BioNTech SE (BNTX) is moving ahead with a Phase II trial of its mpox mRNA...